• Joon Young Song, Hee Jin Cheong, Jacob Lee, Seong-Heon Wie, Kyung-Hwa Park, Sae Yoon Kee, Hye Won Jeong, Yeon-Sook Kim, Ji Yun Noh, Won Suk Choi, Dae Won Park, Jang Wook Sohn, and Woo Joo Kim.
• a Division of Infectious Diseases; Department of Internal Medicine ; Korea University College of Medicine ; Seoul , Korea.
• Hum Vaccin Immunother. 2014 Jan 1; 10 (10): 2958-64.

AbstractInfluenza vaccines are the primary method for preventing influenza and its complications. Considering the increasing demand for influenza vaccines, vaccine manufacturers are required to establish large-scale production systems. This phase IV randomized trial was conducted to evaluate the lot consistency of trivalent split influenza vaccines regarding immunogenicity and safety. A total of 1,023 healthy adults aged 18-64 y were enrolled in the study. Subjects were randomly assigned in a 1:1 ratio to receive the GC FLU® Prefilled Syringe or the GC FLU® Injection, and they were further randomized to one of 3 lots of each vaccine in a 1:1:1 ratio. In both GC FLU® Injection and GC FLU® Prefilled Syringe groups, immune responses were equivalent between lots for each of the 3 vaccine strains on day 21. The 2-sided 95% CI of GMT ratios between pairs of lots were between 0.67 and 1.5, meeting the equivalence criteria. After vaccination, all 3 criteria of the European Medicines Agency were met in both GC FLU® Injection and GC FLU® Prefilled Syringe groups. The vaccines showed tolerable safety profiles without serious adverse events. The demonstration of lot consistency, robust immunogenic responses and favorable safety profiles support the reliability of mass-manufacturing systems for the GC FLU® Injection and GC FLU® Prefilled Syringe.

39 keywords...

hide…